RFC3 Inhibitors
Chemical classes termed RFC3 inhibitors would include agents that can either directly inhibit the RFC3 subunit of the Replication Factor C complex or indirectly impede its function through the modulation of associated pathways. Since direct inhibitors specifically targeting RFC3 are not documented or characterized, the focus is on indirect inhibition through the manipulation of cellular processes that RFC3 is involved in, such as DNA replication and repair.
RFC3 inhibitors interfere with DNA synthesis and repair. By disrupting these processes, they impose replication stress on cells, which in turn can affect the normal function of RFC3, as it is a critical component in the assembly of the replication machinery. DNA damage-inducing inhibitors add to replication stress by creating lesions on DNA that require the replication machinery to engage in repair processes, during which RFC3 plays a significant role. Furthermore, inhibitors impair the repair of DNA single-strand breaks by inhibiting PARP, can lead to the collapse of replication forks, a scenario where the RFC complex is essential for recovery and repair. Nucleoside analogs like gemcitabine and fludarabine are incorporated into DNA during replication, leading to chain termination and subsequent challenges to replication processes involving RFC3. UCN-01's inhibition of cell cycle-regulating kinases can alter the timing and progression of replication, indirectly affecting RFC3's function in coordinating DNA synthesis. Brefeldin A, though primarily affecting membrane transport, can also lead to a cellular environment that indirectly impacts DNA replication and the function of replication factors like RFC3.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Aphidicolin | 38966-21-1 | sc-201535 sc-201535A sc-201535B | 1 mg 5 mg 25 mg | $82.00 $300.00 $1082.00 | 30 | |
Inhibits DNA polymerase, thus indirectly affecting RFC3 by inhibiting the replication fork progression. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
Stabilizes the DNA-topoisomerase I complex, leading to DNA damage and potentially impacting RFC3 activity. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $32.00 $170.00 $385.00 | 63 | |
Inhibits DNA topoisomerase II, causing DNA strand breaks and potentially altering RFC3 function during repair. | ||||||
Hydroxyurea | 127-07-1 | sc-29061 sc-29061A | 5 g 25 g | $76.00 $255.00 | 18 | |
Inhibits ribonucleotide reductase, reducing deoxyribonucleotide pools and indirectly affecting RFC3 activity. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $76.00 $216.00 | 101 | |
Forms DNA adducts, leading to replication stress which can indirectly affect RFC3 as part of the repair process. | ||||||
2′-Deoxy-2′,2′-difluorocytidine | 95058-81-4 | sc-275523 sc-275523A | 1 g 5 g | $56.00 $128.00 | ||
Nucleoside analog that can cause stalling of DNA replication, indirectly affecting RFC3's role. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $65.00 $99.00 $140.00 | 85 | |
Forms DNA crosslinks, potentially hindering the function of RFC3 in replication. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $206.00 $299.00 $485.00 | 10 | |
PARP inhibitor, induces replication stress which can indirectly affect RFC3 activity during repair. | ||||||
Fludarabine | 21679-14-1 | sc-204755 sc-204755A | 5 mg 25 mg | $57.00 $200.00 | 15 | |
Inhibits DNA synthesis, causing DNA damage, which may indirectly impact RFC3's function in DNA repair. | ||||||
β-Lapachone | 4707-32-8 | sc-200875 sc-200875A | 5 mg 25 mg | $110.00 $450.00 | 8 | |
Targets NQO1 bioactivatable drug, causing DNA damage and potentially affecting RFC3 during repair processes. | ||||||